Hematopoietic stem cell mobilization with plerixafor in sickle cell disease.

about

Hematopoietic stem cell mobilization with plerixafor in sickle cell disease.

Item

http://www.wikidata.org/entity/Q55004812

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Hematopoietic stem cell mobilization with plerixafor in sickle cell disease.

@en

Hematopoietic stem cell mobilization with plerixafor in sickle cell disease.

@nl

type

Item

label

Hematopoietic stem cell mobilization with plerixafor in sickle cell disease.

@en

Hematopoietic stem cell mobilization with plerixafor in sickle cell disease.

@nl

prefLabel

Hematopoietic stem cell mobilization with plerixafor in sickle cell disease.

@en

Hematopoietic stem cell mobilization with plerixafor in sickle cell disease.

@nl

P1476

Hematopoietic stem cell mobilization with plerixafor in sickle cell disease.

@en

P2093

John F Tisdale

http://www.w3.org/2001/XMLSchema#string

Matthew M Hsieh

http://www.w3.org/2001/XMLSchema#string

P2860

Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor

Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial.

Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?

Bone Marrow as a Hematopoietic Stem Cell Source for Gene Therapy in Sickle Cell Disease: Evidence from Rhesus and SCD Patients.

Comparison of retroviral transduction efficiency in CD34+ cells derived from bone marrow versus G-CSF-mobilized or G-CSF plus stem cell factor-mobilized peripheral blood in nonhuman primates.

Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results.

Plerixafor enables the safe, rapid, efficient mobilization of haematopoietic stem cells in sickle cell disease patients after exchange transfusion.

P304

749-750

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3324/HAEMATOL.2018.190876

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29712818

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease

P932

5927977

http://www.w3.org/2001/XMLSchema#string